Risk-adapted treatment strategies have constituted a major issue since the beginning of clinical research into @entity978 ( @entity978 ). Various prognostic factors have been identified and several of those considered for staging procedures, resulting in strictly stage-dependent treatment recommendations for @entity1 suffering from @entity978 . These factors may be subdivided in host-related (e.g. age, sex) and @entity5 -related (e.g. number of @entity5 cells, growth characteristics, @entity5 cells, resistance to apoptosis) factors. Owing to the striking improvement of the overall prognosis in @entity978 @entity1 it may be difficult to identify novel prognostic factors analysing the minority of @entity1 with a fatal outcome. However, especially in @entity5 , improved treatment results were achieved by the introduction of more aggressive treatment regimens, resulting in an increased @entity137 rate. Thus, partially in contrast to earlier work in this field, future prognostic factors are needed for identification of those @entity1 that have a good prognosis and might be susceptible to overtreatment. During the Fifth International Symposium on @entity978 , promising results on several new prognostic markers were presented. Furthermore, a joint effort to design new studies on large, well characterised @entity1 groups has been initiated.

Prognostic factors in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity978 :: ('MESH:D006689', 'Disease') :: ["Hodgkin's Lymphoma", 'HD', "Hodgkin's disease"] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['spread of tumour', 'advanced-stage disease', 'tumour']
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin's lymphoma']
